glp-1 vs glp 3 Emerging Frontiers in Therapeutics: A Comprehensive Evidence Base (2025) Frontiers | Revisiting food addiction

Semaglutide and Tirzepatide both reduce appetite and slow digestion, helping with weight loss

doi: 10.1186/s10020-021-00371-7

Additionally, Members of the European Parliament held their inaugural meeting, signalling political commitment and initiating dialogue on obesity priorities across member states

GLP-1 receptor agonists are a class of medications originally developed for type 2 diabetes that have also been FDA approved (in their brand-name forms) for weight management in certain patients

(2018) 153:e183617

Understanding these potential mechanisms helps clinicians counsel patients appropriately and distinguish between expected treatment effects and concerning adverse reactions